Irritable Bowel Syndrome

The IB-Stim device uses electrical pulses to stimulate cranial nerves and reduce pain associated with irritable bowel syndrome.

Preston Klassen, MD, executive vice president of Arena Pharmaceuticals, discusses potential uses for etrasimod outside of inflammatory bowel disease

Preston Klassen, MD, head of research and development at Arena Pharmaceuticals, discusses olorinab's efficacy and safety for the treatment of abdominal pain in Crohn's disease.

Preston Klassen, MD, head of research and development at Arena Pharmaceuticals, discusses a post hoc analysis of biomarkers and clinical outcomes in patients with ulcerative colitis receving etrasimod.

Preston Klassen, MD, head of research and development at Arena Pharamaceuticals, discusses mucosal healing and histologic remission in patients with ulcerative colitis receiving etrasimod.

Overconfidence, anchoring errors, biases, and other factors have all led to misdiagnoses at points in my internal medicine career.

Originally approved in 2002, tegaserod (Zelnorm) was withdrawn in 2007 due to potential safety concerns.

Antibiotic use is believed to be a C difficile infection risk factor for inflammatory bowel disease patients.

Clinical trials consistently demonstrate that fecal microbiota treatment is an effective treatment strategy for recurrent CDI, yet standardization practices vary.

The double-blind, placebo-controlled, parallel-group study that aims to observe linaclotide 290 mcg in 600 adult patients with IBS-C in the US.

Trulance is the only treatment thought to replicate the pH-sensitive activity of uroguanylin.

Eluxadoline — a twice daily, oral medication used to treat adults with IBS-D — is a mu- and kappa-opioid receptor agonist and a delta-opioid receptor antagonist.

Pharma submits sNDA for IBS-C drug plecanatide.

IBS-D treatment eluxadoline is a risk for patients who do not have gallbladders.

New trial tests efficacy of CanChew Plus cannabidiol gum to treat IBS.

HOST-G904 showed positive results for treating severe bowel conditions.

Patients suffering from irritable bowel syndrome with constipation (IBS-C) may benefit from a new drug, plecanatide, making its way through the approval pipeline.

Alternative therapies such as probiotics and synbiotics may be viable options for patients with irritable bowel disorders, according to findings published in the British Journal of Pharmacology.

Patients experiencing pain from irritable bowel syndrome (IBS) might find relief from an unlikely source.

Arachnophobes suffering from irritable bowel syndrome (IBS) may have to put their fear on hold to welcome pain relief from their gastrointestinal condition.

The development of new medications for any condition requires attention to detail in a number of areas, especially safety and efficacy. A recent drug developed for irritable bowel syndrome (IBS) looked to be effective in both areas prior to its approval.